AstraZeneca's Nexium Patent Remains Valid

Law360, New York (November 19, 2007, 12:00 AM EST) -- The European Patent Office has reportedly ruled that a patent covering AstraZeneca Plc's blockbuster heartburn drug Nexium is still valid in its amended form despite challenges from four generic competitors.

AstraZeneca said Monday that its patent, which covers a proton pump inhibitor used in drugs like Nexium and Losec, will now be valid in Austria, Belgium, Switzerland, Germany, Denmark, Spain, France, the United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, the Netherlands, Portugal, Sweden, Latvia, Lithuania and Slovenia until 2015.

ÔÇťAstraZeneca has a comprehensive intellectual property...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.